Regulation Text
Authority
21 U.S.C. 321,343,346,346a,348,350a,350b,352,353,355,360,360c-360f,360h-360j,371,379e,381;42 U.S.C. 216,241,262.
Related Warning Letters (1)
- 2025-03-25
Clinical Investigator
Americo F. Padilla, M.D.
Related Guidelines (10)
Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations: Draft Guidance for Industry (Status: Draft)
→Process for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations: Guidance for Clinical Investigators, Institutional Review Boards and Sponsors (Status: Final)
→Guidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment (Status: Final)
→Exception from Informed Consent Requirements for Emergency Research: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors (Status: Final)
→Premarket Assessment of Pediatric Medical Devices: Guidance for Industry and FDA Staff (Status: Final)
→Vaginal Microbicides:Development for the Prevention of HIV Infection PDF (Status: Final)
→Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry (Status: Final)
→Minutes of Institutional Review Board (IRB) Meetings: Guidance for Institutions and IRBs (Status: Final)
→Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry (Status: Draft)
→E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population (Status: Final)
→